Exchange: NASDAQ·Updated 07:53 PM EDT
DXCM logo

DXCMDexcom Inc

$72.47
$1.24
(1.74%)
Today
Closed $72.47
$0.75
(1.03%)
After Hours
EarningsJul 29
Mkt Cap$27.96B
Vol8.57M
News
all
press releases
Here's How Much You Would Have Made Owning DexCom Stock In The Last 20 Years
read more...
Benzinga
News Placeholder
More News
News Placeholder
DXCM Receives FDA Clearance for Stelo OTC CGM System for Children
DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.
Zacks
News Placeholder
Abbott's CGM Growth Story Stays Intact Despite Q1 Moderation
ABT's CGM sales growth slows in Q1, but management sees a return to double-digit gains as Libre expands with new products and AI tools.
Zacks
News Placeholder
Here's Why DexCom (DXCM) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
News Placeholder
Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes
DexCom CONNECT trial found G7 reduced A1C and improved glucose control in Type 2 diabetes patients not using insulin.read more...
Benzinga
News Placeholder
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes
DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.
Zacks
News Placeholder
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with...
Business Wire
News Placeholder
Here's Why You Should Retain DexCom Stock in Your Portfolio
DXCM banks on CGM market growth, expanding international demand and strong Q1 momentum, though competitive pressures remain a key risk.
Zacks
News Placeholder
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
Key PointsDexCom is a leading innovator in the continuous glucose monitoring market with a global footprint across 52 countries...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.